For patients with BRAF-mutant melanoma, combination treatment with BRAF inhibitors plus MEK inhibitors (BRAFi + MEKi) leads to tumor shrinkage in the majority of patients (1) but tumors progress, with a median progression-free survival (PFS) of approximately 14 months (3). The gene discussed is BRAF; the disease is neoplasm.